p15 Inhibitors
p15 inhibitors belong to a specific chemical class of compounds designed to target and inhibit the activity of the p15 protein. p15, also known as Cyclin-dependent kinase inhibitor 2B (CDKN2B), is a cell cycle regulator that plays a critical role in controlling cell proliferation and cell cycle progression. It belongs to the family of cyclin-dependent kinase inhibitors (CKIs) and acts by inhibiting the activity of cyclin-dependent kinases (CDKs), which are key enzymes that drive cell cycle transitions.
p15 inhibitors work by specifically targeting the p15 protein, interfering with its ability to inhibit CDKs and modulate cell cycle progression. By doing so, these inhibitors may impact cellular proliferation and regulate the progression through different phases of the cell cycle. Research into p15 and its inhibitors is ongoing to unravel their precise mechanisms of action and explore their implications in cellular processes. The study of p15 inhibitors represents an intriguing area of research, contributing to a deeper understanding of the intricate mechanisms governing cell cycle regulation and cell proliferation in various cellular contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Abemaciclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), preventing their interaction with p15, resulting in cell cycle arrest and inhibition of cell proliferation. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
PD 0332991 inhibits CDK4/6, reducing their ability to phosphorylate and inactivate p15, leading to cell cycle arrest and suppression of cancer cell growth. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib targets CDK4/6, disrupting the phosphorylation of p15 and p16, which inhibits G1 to S phase transition in the cell cycle, preventing cell proliferation and tumor growth. | ||||||
BMS-265246 | 582315-72-8 | sc-364440 sc-364440A | 5 mg 10 mg | $304.00 $555.00 | ||
BMS-265246 inhibits CDK4/6, disrupting their phosphorylation of p15 and p16, resulting in cell cycle arrest and inhibition of tumor cell proliferation. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Flavopiridol is a broad-spectrum CDK inhibitor that targets CDK1, CDK2, CDK4, CDK6, and CDK9, among others, indirectly affecting p15, leading to cell cycle arrest and anti-cancer effects. | ||||||
AT7519 | 844442-38-2 | sc-364416 sc-364416A sc-364416B sc-364416C | 5 mg 10 mg 100 mg 1 g | $207.00 $246.00 $1025.00 $3065.00 | 1 | |
AT7519 is a multi-CDK inhibitor that suppresses CDK1, CDK2, CDK4, CDK6, and CDK9, impacting p15-mediated cell cycle regulation and leading to antitumor activity. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032 is a selective CDK inhibitor, blocking CDK2, CDK7, and CDK9, among others, which indirectly affects p15, leading to cell cycle arrest and anti-cancer effects. | ||||||